Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Antitumor activity of motesanib alone and in combination with cisplatin or docetaxel in multiple human non-small-cell lung cancer xenograft models.

Molecular cancer - 19 Sept 2012

Coxon Angela, Ziegler Beth, Kaufman Stephen, Xu Man, Wang Hongyu, Weishuhn Dawn, Schmidt Joanna, Sweet Heather, Starnes Charlie, Saffran Douglas, Polverino Anthony

Abstract excerpt

BACKGROUND: Non-small-cell lung cancer (NSCLC) is categorized into various histologic subtypes that play an important role in prognosis and treatment outcome. We investigated the antitumor activity of motesanib, a selective antagonist of vascular endothelial growth factor receptors (VEGFR) 1, 2,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cisplatin
Share to Docetaxel
Share to Niacinamide

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Oligonucleotides

Share to Taxoids

Share to Tumor Burden

Share to Vascular Endothelial Growth Factor Receptor-2

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 22992329
DOI: 10.1186/1476-4598-11-70
PMCID: PMC3515409

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-22992329-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Antitumor activity of motesanib alone and in combination with cisplatin or docetaxel in multiple human non-small-cell lung cancer xenograft models.PMID 22992329Read ↗

Efficacy of combined icotinib and pemetrexed in EGFR mutant lung adenocarcinoma cell line xenografts.Semantic proximity Read ↗

VEGFR2 blockade augments the effects of tyrosine kinase inhibitors by inhibiting angiogenesis and oncogenic signaling in oncogene-driven non-small-cell lung cancers.Semantic proximity Read ↗

CM082, a novel angiogenesis inhibitor, enhances the antitumor activity of gefitinib on epidermal growth factor receptor mutant non-small cell lung cancer in vitro and in vivo.Semantic proximity Read ↗

Potential Benefits of Bevacizumab Combined With Platinum-Based Chemotherapy in Advanced Non-Small-Cell Lung Cancer Patients With EGFR Mutation.Semantic proximity Read ↗

Anti-tumor activity of motesanib in a medullary thyroid cancer model.Semantic proximity Read ↗

EGFR-directed monoclonal antibodies in non-small cell lung cancer.Semantic proximity Read ↗

Antitumor Activity of RXDX-105 in Multiple Cancer Types with RET Rearrangements or Mutations.Semantic proximity Read ↗

Dual EGFR-VEGF Pathway Inhibition: A Promising Strategy for Patients With EGFR-Mutant NSCLC.Semantic proximity Read ↗

Establishment of patient-derived non-small cell lung cancer xenografts as models for the identification of predictive biomarkers.Semantic proximity Read ↗

Efficacy of nintedanib plus docetaxel in patients with refractory advanced epidermal growth factor receptor mutant lung adenocarcinoma.Semantic proximity Read ↗

KPT-330 has antitumour activity against non-small cell lung cancer.Semantic proximity Read ↗

Phase1 study of cisplatin plus pemetrexed with erlotinib and bevacizumab for chemotherapy-naïve advanced non-squamous non-small cell lung cancer with EGFR mutations.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.